JP2016534092A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016534092A5 JP2016534092A5 JP2016529755A JP2016529755A JP2016534092A5 JP 2016534092 A5 JP2016534092 A5 JP 2016534092A5 JP 2016529755 A JP2016529755 A JP 2016529755A JP 2016529755 A JP2016529755 A JP 2016529755A JP 2016534092 A5 JP2016534092 A5 JP 2016534092A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- antigen
- cl2a
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 claims 21
- 108090001123 antibodies Proteins 0.000 claims 21
- -1 CD3 Proteins 0.000 claims 13
- 239000000427 antigen Substances 0.000 claims 11
- 108091007172 antigens Proteins 0.000 claims 10
- 102000038129 antigens Human genes 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 9
- 239000000543 intermediate Substances 0.000 claims 8
- 238000006243 chemical reaction Methods 0.000 claims 6
- 102100008450 AFP Human genes 0.000 claims 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 4
- 102100010912 EPCAM Human genes 0.000 claims 3
- UCPYLLCMEDAXFR-UHFFFAOYSA-N Triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 claims 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims 2
- 102100007326 BIRC5 Human genes 0.000 claims 2
- 102100001537 CA9 Human genes 0.000 claims 2
- 101710040946 CA9 Proteins 0.000 claims 2
- 102100005826 CD19 Human genes 0.000 claims 2
- 101700087100 CD19 Proteins 0.000 claims 2
- 102100013082 CD1A Human genes 0.000 claims 2
- 101700015984 CD1A Proteins 0.000 claims 2
- 102100000189 CD22 Human genes 0.000 claims 2
- 101700020617 CD22 Proteins 0.000 claims 2
- 102100003729 CD40LG Human genes 0.000 claims 2
- 102100004099 CD74 Human genes 0.000 claims 2
- 101710007476 CD74 Proteins 0.000 claims 2
- 101710043956 CEACAM5 Proteins 0.000 claims 2
- 102100011842 CEACAM5 Human genes 0.000 claims 2
- 102100011839 CEACAM6 Human genes 0.000 claims 2
- 101710043949 CEACAM6 Proteins 0.000 claims 2
- 108060002563 EPCAM Proteins 0.000 claims 2
- 230000035693 Fab Effects 0.000 claims 2
- 108050007372 Fibroblast growth factor family Proteins 0.000 claims 2
- 102000018233 Fibroblast growth factor family Human genes 0.000 claims 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 2
- 229940084986 Human Chorionic Gonadotropin Drugs 0.000 claims 2
- 102100014231 IGF1 Human genes 0.000 claims 2
- 101700074337 IGF1 Proteins 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
- 102100000165 MS4A1 Human genes 0.000 claims 2
- 101710010909 MS4A1 Proteins 0.000 claims 2
- 102100006044 MUC16 Human genes 0.000 claims 2
- 101700008449 MUC16 Proteins 0.000 claims 2
- 108060005162 MYDGF Proteins 0.000 claims 2
- 108010002687 Survivin Proteins 0.000 claims 2
- 101710024898 TACSTD2 Proteins 0.000 claims 2
- 102100018484 TACSTD2 Human genes 0.000 claims 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 2
- 229910052802 copper Inorganic materials 0.000 claims 2
- 239000010949 copper Substances 0.000 claims 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 claims 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims 1
- 101700067361 ACAP1 Proteins 0.000 claims 1
- 102100016909 ACKR3 Human genes 0.000 claims 1
- 101700064578 ACKR3 Proteins 0.000 claims 1
- 102100003649 ACP3 Human genes 0.000 claims 1
- 101700014681 ACTN4 Proteins 0.000 claims 1
- 102100017481 ACTN4 Human genes 0.000 claims 1
- 108010002367 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Proteins 0.000 claims 1
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 208000003950 B-Cell Lymphoma Diseases 0.000 claims 1
- 102100011431 BAGE Human genes 0.000 claims 1
- 108060000856 BAGE Proteins 0.000 claims 1
- 102100013894 BCL2 Human genes 0.000 claims 1
- 108060000885 BCL2 Proteins 0.000 claims 1
- 101700024247 BCL6 Proteins 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 102100008990 CASP8 Human genes 0.000 claims 1
- 101700075287 CASP8 Proteins 0.000 claims 1
- 102100019492 CCL19 Human genes 0.000 claims 1
- 101700049349 CCL19 Proteins 0.000 claims 1
- 102100008428 CCL2 Human genes 0.000 claims 1
- 101700006000 CCL2 Proteins 0.000 claims 1
- 102100012031 CCL21 Human genes 0.000 claims 1
- 101700070431 CCL21 Proteins 0.000 claims 1
- 102100016449 CCL5 Human genes 0.000 claims 1
- 102100003268 CD14 Human genes 0.000 claims 1
- 101700027514 CD14 Proteins 0.000 claims 1
- 101700085585 CD1B Proteins 0.000 claims 1
- 101700019673 CD1C Proteins 0.000 claims 1
- 101700070268 CD1D Proteins 0.000 claims 1
- 102100019289 CD2 Human genes 0.000 claims 1
- 101700024689 CD2 Proteins 0.000 claims 1
- 101710012053 CD274 Proteins 0.000 claims 1
- 102100007290 CD274 Human genes 0.000 claims 1
- 102100016493 CD33 Human genes 0.000 claims 1
- 101700017647 CD33 Proteins 0.000 claims 1
- 102100016530 CD37 Human genes 0.000 claims 1
- 101700044364 CD37 Proteins 0.000 claims 1
- 102100003279 CD38 Human genes 0.000 claims 1
- 101700044948 CD38 Proteins 0.000 claims 1
- 102100013077 CD4 Human genes 0.000 claims 1
- 101700022938 CD4 Proteins 0.000 claims 1
- 102100013137 CD40 Human genes 0.000 claims 1
- 101710040446 CD40 Proteins 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 101700078950 CD44 Proteins 0.000 claims 1
- 102100003735 CD44 Human genes 0.000 claims 1
- 102100019144 CD46 Human genes 0.000 claims 1
- 101710027020 CD46 Proteins 0.000 claims 1
- 102100005828 CD5 Human genes 0.000 claims 1
- 101700066525 CD5 Proteins 0.000 claims 1
- 102100019283 CD52 Human genes 0.000 claims 1
- 108010065524 CD52 Antigen Proteins 0.000 claims 1
- 102100013391 CD55 Human genes 0.000 claims 1
- 101710006195 CD55 Proteins 0.000 claims 1
- 102100003281 CD59 Human genes 0.000 claims 1
- 101700073334 CD59 Proteins 0.000 claims 1
- 102100005830 CD70 Human genes 0.000 claims 1
- 101700017377 CD70 Proteins 0.000 claims 1
- 102100019451 CD80 Human genes 0.000 claims 1
- 101700080477 CD80 Proteins 0.000 claims 1
- 101700013105 CD83 Proteins 0.000 claims 1
- 102100008186 CD83 Human genes 0.000 claims 1
- 102100008191 CD8A Human genes 0.000 claims 1
- 101700054655 CD8A Proteins 0.000 claims 1
- 102100013075 CDC27 Human genes 0.000 claims 1
- 101700008359 CDK4 Proteins 0.000 claims 1
- 102000033243 CDKN2A Human genes 0.000 claims 1
- 101700020447 CR2 Proteins 0.000 claims 1
- 102100009368 CR2 Human genes 0.000 claims 1
- 102100011494 CSAG2 Human genes 0.000 claims 1
- 101700073572 CSAG2 Proteins 0.000 claims 1
- 102100001891 CTAG1A Human genes 0.000 claims 1
- 101710004449 CTAG1A Proteins 0.000 claims 1
- 102100005284 CTAG2 Human genes 0.000 claims 1
- 101700050838 CTAG2 Proteins 0.000 claims 1
- 101700054183 CTLA4 Proteins 0.000 claims 1
- 102100005310 CTLA4 Human genes 0.000 claims 1
- 102100014691 CXCL12 Human genes 0.000 claims 1
- 101710043128 CXCL12 Proteins 0.000 claims 1
- 102100009664 CXCL2 Human genes 0.000 claims 1
- 102100002212 CXCR4 Human genes 0.000 claims 1
- 101710003734 CXCR4 Proteins 0.000 claims 1
- 241000282836 Camelus dromedarius Species 0.000 claims 1
- 102000008646 Carbonic Anhydrase IX Human genes 0.000 claims 1
- 108010088013 Carbonic Anhydrase IX Proteins 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 1
- 210000001072 Colon Anatomy 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 claims 1
- 101700025368 ERBB2 Proteins 0.000 claims 1
- 102100016662 ERBB2 Human genes 0.000 claims 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 1
- 101700079540 FAS Proteins 0.000 claims 1
- 102100016439 FAS Human genes 0.000 claims 1
- 101700053597 FCER2 Proteins 0.000 claims 1
- 102100014608 FCER2 Human genes 0.000 claims 1
- 102100015540 FCGR1A Human genes 0.000 claims 1
- 101710003440 FCGR1A Proteins 0.000 claims 1
- 102100015541 FCGR3A Human genes 0.000 claims 1
- 101710044656 FCGR3A Proteins 0.000 claims 1
- 101710044657 FCGR3B Proteins 0.000 claims 1
- 102100007407 FGF6 Human genes 0.000 claims 1
- 101700012851 FGF6 Proteins 0.000 claims 1
- 101700010580 FLO11 Proteins 0.000 claims 1
- 101710030892 FLT1 Proteins 0.000 claims 1
- 101710009074 FLT3 Proteins 0.000 claims 1
- 102100008658 FN1 Human genes 0.000 claims 1
- 102100008453 FOLH1 Human genes 0.000 claims 1
- 101700036477 FOLH1 Proteins 0.000 claims 1
- 102100019327 FUT4 Human genes 0.000 claims 1
- 101700004786 FUT4 Proteins 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 229940014144 Folate Drugs 0.000 claims 1
- 101700054376 GROB Proteins 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 102100016996 HHAT Human genes 0.000 claims 1
- 108060004720 HHAT Proteins 0.000 claims 1
- 101700056516 HIF1 Proteins 0.000 claims 1
- 102100003042 HIF1A Human genes 0.000 claims 1
- 101700000053 HIF1A Proteins 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 102100004115 ICAM1 Human genes 0.000 claims 1
- 101700051176 ICAM1 Proteins 0.000 claims 1
- 101700046422 IFNA Proteins 0.000 claims 1
- 101700011451 IFNB1 Proteins 0.000 claims 1
- 102100015720 IFNB1 Human genes 0.000 claims 1
- 101700086956 IFNG Proteins 0.000 claims 1
- 102100016020 IFNG Human genes 0.000 claims 1
- 102100004549 IL13RA2 Human genes 0.000 claims 1
- 102100006815 IL2RA Human genes 0.000 claims 1
- 101700082799 IL2RA Proteins 0.000 claims 1
- 101700015336 ISG20 Proteins 0.000 claims 1
- 101710006573 ITGAL Proteins 0.000 claims 1
- 102100019442 ITGAL Human genes 0.000 claims 1
- 102100001478 ITGB1 Human genes 0.000 claims 1
- 101710006661 ITGB1 Proteins 0.000 claims 1
- 101710006663 ITGB2 Proteins 0.000 claims 1
- 102100001475 ITGB2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102100013180 KDR Human genes 0.000 claims 1
- 101700058542 KLK3 Proteins 0.000 claims 1
- 101710033922 KRAS Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102100012644 MIF Human genes 0.000 claims 1
- 108060004872 MIF Proteins 0.000 claims 1
- 102100008857 MLANA Human genes 0.000 claims 1
- 101710012533 MLANA Proteins 0.000 claims 1
- 102100006037 MUC1 Human genes 0.000 claims 1
- 101700052761 MUC1 Proteins 0.000 claims 1
- 101700086625 MUC13 Proteins 0.000 claims 1
- 102100009404 MUC13 Human genes 0.000 claims 1
- 101700010570 MUC17 Proteins 0.000 claims 1
- 102100013951 MUC2 Human genes 0.000 claims 1
- 101700036633 MUC2 Proteins 0.000 claims 1
- 102100013952 MUC3A Human genes 0.000 claims 1
- 101700075415 MUC3A Proteins 0.000 claims 1
- 102100013929 MUC4 Human genes 0.000 claims 1
- 101700032853 MUC4 Proteins 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 101700001465 NBR1 Proteins 0.000 claims 1
- 102100011126 NOB1 Human genes 0.000 claims 1
- 108060005497 NOB1 Proteins 0.000 claims 1
- 102100002997 NPEPPS Human genes 0.000 claims 1
- 101710027788 NPEPPS Proteins 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 229920000272 Oligonucleotide Polymers 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 101710043203 P23p89 Proteins 0.000 claims 1
- 102100019764 PDCD1 Human genes 0.000 claims 1
- 102100012897 PGF Human genes 0.000 claims 1
- 101710014083 PGF Proteins 0.000 claims 1
- 101710008823 PLAGL2 Proteins 0.000 claims 1
- 102100012910 PLAGL2 Human genes 0.000 claims 1
- 108060006580 PRAME Proteins 0.000 claims 1
- 102100006759 PRAME Human genes 0.000 claims 1
- 101710025567 PSAT1 Proteins 0.000 claims 1
- 101700008337 PSMA Proteins 0.000 claims 1
- 102100005499 PTPRC Human genes 0.000 claims 1
- 101700059076 PTPRC Proteins 0.000 claims 1
- 102100009677 PWWP3A Human genes 0.000 claims 1
- 108060006838 PWWP3A Proteins 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 102000000034 Programmed Cell Death 1 Receptor Human genes 0.000 claims 1
- 108010080196 Programmed Cell Death 1 Receptor Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 101710037934 QRSL1 Proteins 0.000 claims 1
- 101700013615 RFS5 Proteins 0.000 claims 1
- 101700044827 RNMT Proteins 0.000 claims 1
- 206010038038 Rectal cancer Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 108060007796 SPATA2 Proteins 0.000 claims 1
- 235000002912 Salvia officinalis Nutrition 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 229940014598 TAC Drugs 0.000 claims 1
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 claims 1
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 claims 1
- 101710040533 TNFRSF8 Proteins 0.000 claims 1
- 102100009538 TNFRSF8 Human genes 0.000 claims 1
- 102100019730 TP53 Human genes 0.000 claims 1
- 101710026335 TP53 Proteins 0.000 claims 1
- 102100003485 TRAF3 Human genes 0.000 claims 1
- 102000007000 Tenascin Human genes 0.000 claims 1
- 108010008125 Tenascin Proteins 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 231100000765 Toxin Toxicity 0.000 claims 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 206010054094 Tumour necrosis Diseases 0.000 claims 1
- 206010046766 Uterine cancer Diseases 0.000 claims 1
- 108091007928 VEGF receptors Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 201000005216 brain cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000007806 chemical reaction intermediate Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000000295 complement Effects 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 238000006352 cycloaddition reaction Methods 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 1
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 claims 1
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000037320 fibronectin Effects 0.000 claims 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 230000001146 hypoxic Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002452 interceptive Effects 0.000 claims 1
- 108040003607 interleukin-13 receptor activity proteins Proteins 0.000 claims 1
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 claims 1
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 claims 1
- 108040001304 interleukin-17 receptor activity proteins Proteins 0.000 claims 1
- 108040002014 interleukin-18 receptor activity proteins Proteins 0.000 claims 1
- 102000008625 interleukin-18 receptor activity proteins Human genes 0.000 claims 1
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 claims 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 238000011031 large scale production Methods 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- 208000009018 medullary Thyroid cancer Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims 1
- 108091008124 oncoproteins Proteins 0.000 claims 1
- 102000025475 oncoproteins Human genes 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 230000001376 precipitating Effects 0.000 claims 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 235000002020 sage Nutrition 0.000 claims 1
- 239000001296 salvia officinalis l. Substances 0.000 claims 1
- 238000010898 silica gel chromatography Methods 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Claims (16)
- SN−38をtert−ブチルジメチルシリルクロリド(TBDMS−Cl)と反応させて、10−O−TBDMS−SN−38(中間体4)を生成することをさらに含み、前記反応はジクロロメタン溶媒中で実施される、請求項1に記載の方法。
- 10−O−TBDMS−SN−38(中間体4)をトリホスゲン及びDMAPと反応させて10−O−TBDMS−SN−38−20−O−クロロギ酸(反応中間体5)を生成することをさらに含み、ここで、前記反応はトリホスゲンを、中間体4を含有するジクロロメタン反応混合物へ添加することによって実行され、かつ前記トリホスゲンは少量ずつ添加されて、大規模製造中の発熱反応を低下させかつ高い反応収量を維持する、請求項1に記載の方法。
- Lys(MMT)−PABOH(中間体2)をヘプタンで沈殿させることをさらに含む、請求項1に記載の方法。
- 銅触媒で触媒した付加環化反応によってアジド−PEG−Lys(MMT)−PABO−CO−20−O−SN−38(中間体7)をMCC−Yne(中間体8)と反応させて、MCC−PEG−Lys(MMT)−PABO−CO−20−O−SN−38(中間体9)を生成することをさらに含み、前記反応は14時間実施して生成収量を改善する、請求項1に記載の方法。
- 中間体9はシリカゲルクロマトグラフィーによってまず精製され、次いでEDTAを用いて抽出して銅を除去する、請求項5に記載の方法。
- CL2A−SN38のマレイミド部分を抗体または抗原結合抗体フラグメントと反応させて、SN38−結合抗体または抗体フラグメントを生成することをさらに含む、請求項1に記載の方法。
- 前記抗体フラグメントは、F(ab’)2、F(ab)2、Fab’、Fab、Fv、scFv、単一ドメイン抗体及びIgG4抗体の半分子からなる群から選択される、請求項7に記載の方法。
- 前記抗体または抗体フラグメントは、1コピー〜12コピーのCL2A−SN38へ結合する、請求項7に記載の方法。
- 前記抗体は、LL1(抗CD74)、LL2(抗CD22)、RFB4(抗CD22)、RS7(抗EGP−1)、PAM4(抗MUC5AC)、KC4(抗ムチン)、A19(抗CD19)、A20(抗CD20)、MN−14(抗CEACAM5)、MN−15(抗CEACAM6)、MN−3(抗CEACAM6)、R1(抗IGF−1R)、Mu−9(抗CSAp)、Immu31(抗AFP)、CC49(抗TAG−72)、J591(抗PSMA)、HuJ591(抗PSMA)、AB−PG1−XG1−026(抗PSMA二量体)、D2/B(抗PSMA)、G250(抗炭酸脱水酵素IX)及びhL243(抗HLA−DR)からなる群から選択される、請求項7に記載の方法。
- 前記抗体または抗体フラグメントは、炭酸脱水酵素IX、α−フェトプロテイン(AFP)、α−アクチニン4、ART−4、B7、Ba733、BAGE、BrE3−抗原、CA125、CAMEL、CAP−1、CASP−8/m、CCL19、CCL21、CD1、CD1a、CD2、CD3、CD4、CD5、CD8、CD11A、CD14、CD15、CD16、CD18、CD19、CD20、CD21、CD22、CD23、CD25、CD29、CD30、CD32b、CD33、CD37、CD38、CD40、CD40L、CD44、CD45、CD46、CD52、CD54、CD55、CD59、CD64、CD66a〜e、CD67、CD70、CD70L、CD74、CD79a、CD80、CD83、CD95、CD126、CD132、CD133、CD138、CD147、CD154、CDC27、CDK−4/m、CDKN2A、CTLA−4、CXCR4、CXCR7、CXCL12、HIF−1α、結腸特異的抗原p(CSAp)、CEACAM5、CEACAM6、c−Met、DAM、EGFR、EGFRvIII、EGP−1(TROP−2)、EGP−2、ELF2−M、Ep−CAM、線維芽細胞増殖因子(FGF)、Flt−1、Flt−3、葉酸受容体、G250抗原、GAGE、gp100、GRO−β、H2B、H3、H4、HLA−DR、HM1.24、ヒト絨毛性ゴナドトロピン(HCG)、HER2/neu、HMGB−1、低酸素誘導因子(HIF−1)、HSP70−2M、HST−2、Ia、IGF−1R、IFN−γ、IFN−α、IFN−β、IFN−λ、IL−4R、IL−6R、IL−13R、IL−15R、IL−17R、IL−18R、IL−2、IL−6、IL−8、IL−12、IL−15、IL−17、IL−18、IL−23、IL−25、インスリン様増殖因子1(IGF−1)、KS1−4、Le−Y、LDR/FUT、マクロファージ遊走阻止因子(MIF)、MAGE、MAGE−3、MART−1、MART−2、NY−ESO−1、TRAG−3、mCRP、MCP−1、MIP−1A、MIP−1B、MIF、MUC1、MUC2、MUC3、MUC4、MUC5ac、MUC13、MUC16、MUM−1/2、MUM−3、NCA66、NCA95、NCA90、PD−1、PD−L1、PD−1受容体、胎盤増殖因子、p53、PLAGL2、前立腺酸性ホスファターゼ、PSA、PRAME、PSMA、PlGF、ILGF、ILGF−1R、IL−6、IL−25、RS5、RANTES、T101、SAGE、S100、サバイビン、サバイビン2B、TAC、TAG−72、テネイシン、TRAIL受容体、TNF−α、Tn抗原、トムソン・フリーデンライヒ抗原、腫瘍壊死性抗原(tumor necrosis antigen)、VEGFR、ED−Bフィブロネクチン、WT−1、17−1A抗原、補体因子C3、C3a、C3b、C5a、C5、bcl−2、bcl−6、Kras、ならびに癌遺伝子産物からなる群から選択される抗原へ結合する、請求項7に記載の方法。
- 前記抗体または抗体フラグメントは、EGP−1(TROP−2)、CEACAM5、CEACAM6、CD74、CD19、CD20、CD22、CSAp、HLA−DR、MUC5ac、及びAFP(α−フェトプロテイン)からなる群から選択される抗原へ結合するものであり、前記治療剤は、抗体−CL2A−SN−38複合体が3mg/kgと18mg/kgの間の薬用量で投与されるように用いられる、請求項12に記載の治療剤。
- 前記抗体は、hLL1(抗CD74)、hLL2(抗CD22)、hRFB4(抗CD22)、hRS7(抗TROP−2)、hPAM4(抗MUC5ac)、hMN−3(抗CEACAM6)、hMN−14(抗CEACAM5)、hMN−15(抗CEACAM6)、hA19(抗CD19)、hA20(抗CD22)、hMu−9(抗CSAp)、hL243(抗HLA−DR)及びhIMMU31(抗AFP)からなる群から選択される、請求項12に記載の治療剤。
- 前記癌は、B細胞リンパ腫、B細胞白血病、結腸癌、胃癌、食道癌、甲状腺髄様癌、腎癌、乳癌、肺癌、膵癌、膀胱癌、卵巣癌、子宮癌、子宮頸癌、精巣癌、前立腺癌、肝癌、皮膚癌、骨癌、脳癌、直腸癌、及び黒色腫からなる群から選択される、請求項12に記載の治療剤。
- 抗体−CL2A−SN−38複合体が、非結合型抗体、放射性標識抗体、薬剤結合型抗体、毒素結合型抗体、遺伝子療法、化学療法、治療用ペプチド、サイトカイン療法、オリゴヌクレオチド、限局性放射線療法、手術及び干渉性RNA療法からなる群から選択される1つ以上の治療様式と組み合わせて投与されるように用いられる、請求項12に記載の治療剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/948,732 US9028833B2 (en) | 2012-12-13 | 2013-07-23 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
US13/948,732 | 2013-07-23 | ||
PCT/US2014/034518 WO2015012904A2 (en) | 2012-12-13 | 2014-04-17 | Antibody-sn-38 immunoconjugates with a cl2a linker |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016534092A JP2016534092A (ja) | 2016-11-04 |
JP2016534092A5 true JP2016534092A5 (ja) | 2017-04-27 |
JP6427789B2 JP6427789B2 (ja) | 2018-11-28 |
Family
ID=54873835
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016529755A Active JP6427789B2 (ja) | 2013-07-23 | 2014-04-17 | Cl2aリンカーを有する抗体−sn−38免疫複合体 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3024460B1 (ja) |
JP (1) | JP6427789B2 (ja) |
CN (2) | CN105407891A (ja) |
AU (1) | AU2014293670B2 (ja) |
CA (1) | CA2914438C (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3464280B1 (en) * | 2016-06-06 | 2021-10-06 | F. Hoffmann-La Roche AG | Silvestrol antibody-drug conjugates and methods of use |
CN109562172B (zh) * | 2016-08-11 | 2022-08-16 | 免疫医疗公司 | 抗HLA-DR抗体药物缀合物IMMU-140(hL243-CL2A-SN-38)在HLA-DR阳性癌症中的功效 |
CN108066772B (zh) * | 2016-11-14 | 2021-07-13 | 中国科学院上海药物研究所 | 靶向tacstd2的抗体与药物偶联体(adc)分子 |
WO2018102212A1 (en) * | 2016-12-01 | 2018-06-07 | Immunomedics, Inc. | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (immu-132) |
JP7204132B2 (ja) * | 2017-05-02 | 2023-01-16 | 国立研究開発法人国立がん研究センター | プラスミンにより切断可能な抗不溶性フィブリン抗体と薬物とのコンジュゲート |
CA3080236A1 (en) * | 2017-12-15 | 2019-06-20 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Bioactive molecule conjugate, preparation method and use thereof |
CN111542324B (zh) * | 2018-02-11 | 2023-09-12 | 四川科伦博泰生物医药股份有限公司 | 细胞毒性剂及其偶联物、其制备方法及用途 |
WO2019195770A1 (en) * | 2018-04-06 | 2019-10-10 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2 antibodies |
CN113454108A (zh) * | 2019-01-23 | 2021-09-28 | 米伦纽姆医药公司 | 包含去免疫化志贺菌毒素a亚基效应子的cd38结合蛋白 |
WO2021121204A1 (zh) * | 2019-12-16 | 2021-06-24 | 江苏恒瑞医药股份有限公司 | 抗cea抗体-依喜替康类似物偶联物及其医药用途 |
EP4095148A4 (en) | 2020-01-22 | 2023-07-26 | Jiangsu Hengrui Medicine Co., Ltd. | ANTI-TROP-2 ANTIBODY EXATECAN ANALOGUE CONJUGATE AND MEDICAL USE THEREOF |
CN111499685A (zh) * | 2020-03-30 | 2020-08-07 | 联宁(苏州)生物制药有限公司 | 具有马来酰亚胺连接头的抗体偶联药物中间体及其合成方法 |
CN113527498B (zh) * | 2020-04-16 | 2022-03-04 | 上海洛启生物医药技术有限公司 | 抗Trop2纳米抗体及其应用 |
CN113480651B (zh) * | 2021-07-19 | 2022-07-08 | 华东师范大学 | 一种靶向人cd133的纳米抗体及其制备方法和应用 |
AU2022314086A1 (en) | 2021-07-21 | 2024-02-22 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition containing anti-trop2 antibody drug conjugate and use thereof |
WO2023198200A1 (zh) * | 2022-04-14 | 2023-10-19 | 苏州瑞博生物技术股份有限公司 | 缀合物与组合物及制备方法和用途 |
CN114917222B (zh) * | 2022-04-29 | 2023-02-28 | 佛山病原微生物研究院 | 一种Ganetespib在制备用于抗腺病毒感染的药物中的用途 |
CN116139267A (zh) * | 2023-01-28 | 2023-05-23 | 华中科技大学同济医学院附属同济医院 | 小鼠cd74单克隆抗体在制备治疗肿瘤药物中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0028361D0 (en) * | 2000-11-21 | 2001-01-03 | Glaxo Group Ltd | Method of separating extra chromosomal dna from other cellular components |
SE0104462D0 (sv) * | 2001-12-29 | 2001-12-29 | Carlbiotech Ltd As | Peptide purifcation (Peptidrening) |
US8420086B2 (en) * | 2002-12-13 | 2013-04-16 | Immunomedics, Inc. | Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases |
CN102448494B (zh) * | 2009-02-13 | 2016-02-03 | 免疫医疗公司 | 具有胞内可裂解的键的免疫共轭物 |
WO2011100131A2 (en) * | 2010-01-28 | 2011-08-18 | Alnylam Pharmacuticals, Inc. | Monomers and oligonucleotides comprising cycloaddition adduct(s) |
CA2884313C (en) * | 2012-12-13 | 2023-01-03 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity |
-
2014
- 2014-04-17 AU AU2014293670A patent/AU2014293670B2/en active Active
- 2014-04-17 CN CN201480041766.2A patent/CN105407891A/zh active Pending
- 2014-04-17 CA CA2914438A patent/CA2914438C/en active Active
- 2014-04-17 JP JP2016529755A patent/JP6427789B2/ja active Active
- 2014-04-17 EP EP14828674.3A patent/EP3024460B1/en active Active
- 2014-04-17 CN CN201910347750.9A patent/CN110075295A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016534092A5 (ja) | ||
JP2016520548A5 (ja) | ||
US20200345854A1 (en) | Bispecific antibody capable of being combined with immune cells to enhance tumor killing capability, and preparation method therefor and application thereof | |
JP2016513098A5 (ja) | ||
JP2012500286A5 (ja) | ||
US10669338B2 (en) | Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1 | |
US10040848B2 (en) | Chimeric and humanized anti-histone antibodies | |
CN107735090B (zh) | 具有cl2a接头的抗体-sn-38免疫缀合物 | |
JP2013503184A5 (ja) | ||
US9797907B2 (en) | Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells | |
FI3903829T3 (fi) | Solunsisäisesti katkeavan sidoksen omaavia immunokonjugaatteja | |
JPWO2020021045A5 (ja) | ||
JP2014514345A5 (ja) | ||
US20160361360A1 (en) | Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs | |
JP6427789B2 (ja) | Cl2aリンカーを有する抗体−sn−38免疫複合体 | |
US20150344573A1 (en) | Humanized anti-cd22 antibody | |
US10988539B2 (en) | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers | |
JP2017536340A (ja) | 抗体−薬物コンジュゲートのネオアジュバント使用 | |
US20190083487A1 (en) | EFFICACY OF ANTI-HLA-DR ANTIBODY DRUG CONJUGATE IMMU-140 (hL243-CL2A-SN-38) IN HLA-DR POSITIVE CANCERS | |
WO2015069430A2 (en) | Humanized anti-ceacam5 antibody and uses thereof | |
US20200338128A1 (en) | Precision molecular adaptor system for car-t immunotherapy | |
CA3107938C (en) | Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof | |
Wang et al. | CAR-T cells: the Chinese experience | |
EP3496754A1 (en) | EFFICACY OF ANTI-HLA-DR ANTIBODY DRUG CONJUGATE IMMU-140 (hL243-CL2A-SN-38) IN HLA-DR POSITIVE CANCERS | |
Byun et al. | Chimeric antigen receptor-T cell therapy |